针对a型流感嗜血杆菌的潜在候选疫苗的成本效益
研究采用基于个体的模拟模型,参数化自加拿大努纳武特地区各年龄别发病率,评估按照加拿大b型流感嗜血杆菌(Hib)现行婴儿常规免疫程序接种Hia结合疫苗的成本效益。
要点
- 基于努纳武特年龄别发病率的个体模拟模型显示Hia结合疫苗极具成本效益。
- 10年基础免疫覆盖率77%、加强剂覆盖率93%使侵袭性疾病平均减少63.8%。
核心结论
- 研究结果表明Hia结合疫苗在管理作为日益增长公共卫生威胁的Hia疾病方面可发挥重要作用。
研究设计与样本
- 研究开发并参数化了一个基于个体的模拟模型,使用加拿大努纳武特地区报告的年龄别发病率,评估按照加拿大Hib现行婴儿常规免疫程序接种Hia疫苗的成本效益。
主要发现
- 10年期间基础免疫覆盖率77%、加强剂覆盖率93%使侵袭性疾病发病率平均降低63.8%,从9.97例/10万人降至3.61例/10万人。
关键数值与推荐
- 基于增量成本效益比统计分析的结果显示,Hia结合疫苗极具成本效益。
- 模拟的免疫程序为10年期间基础免疫覆盖率77%、加强剂覆盖率93%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The preceding decade has witnessed the emergence of severe community-acquired acute infections caused by Haemophilus influenzae serotype a (Hia), with alarming incidence rates in North America, particularly among indigenous populations. The remarkable success of Hib conjugate vaccine over the past 20 years signify the development of an Hia vaccine candidate as a prevention measure to reduce the incidence of invasive Hia disease. However, quantifications of the long-term epidemiologic and economic impacts of vaccination are needed to inform decision on investment in Hia vaccine development and immunization programs. We sought to evaluate the cost-effectiveness of an Hia vaccine with a similar routine infant immunization schedules currently in practice for Hib in Canada. We developed and parameterized an agent-based simulation model using age-specific incidence rates reported for Nunavut, a Canadian territory with predominantly aboriginal populations. Our results, based on statistical analyses of the incremental cost-effectiveness ratio, show that an Hia conjugate vaccine is highly cost-effective. Sustaining an immunization program with vaccine coverages of 77% for primary series and 93% for booster dose over a 10-year period reduces the incidence of invasive disease by 63.8% on average from 9.97 to 3.61 cases, per 100,000 population. The overall costs of disease management in year 10 are reduced by 53.4% from CDN $1.863 million (95% CI: $1.229-$2.519 M) to CDN $0.868 million (95% CI: $0.627-$1.120 M). The findings suggest an important role for a conjugate vaccine in managing Hia disease as a growing public health threat.
引用
- Shoukat A, Van Exan R, Moghadas SM, et al. Cost-effectiveness of a potential vaccine candidate for Haemophilus influenzae serotype 'a'. Vaccine. 2018. PMID: 29459062. doi:10.1016/j.vaccine.2018.01.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。